NASDAQ:PHVS

Pharvaris Stock Forecast, Price & News

$28.75

-4.86 (-14.46 %)

(As of 03/5/2021 12:00 AM ET)

Add

Compare

Today's Range

$28.14

Now: $28.75▼

$34.62

50-Day Range N/A

52-Week Range

$23.06

Now: $28.75▼

$42.86

Volume139,847 shs

Average Volume186,676 shs

Market Capitalization$915.40 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Pharvaris B.V., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:PHVS

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.pharvaris.com

Phone31 71 203 6410

EmployeesN/A

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares31,840,000

Market Cap$915.40 million

Next Earnings DateN/A

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.44 out of 5 stars

Medical Sector

585th out of 1,972 stocks

Biotechnology Industry

20th out of 125 stocks

3.4 Analyst's Opinion

Consensus Rating
Pharvaris has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $47.50, Pharvaris has a forecasted upside of 65.2% from its current price of $28.75.
Amount of Analyst Coverage
Pharvaris has only been the subject of 4 research reports in the past 90 days.

3.8 Community Rank

Outperform Votes
Pharvaris has received 3 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Pharvaris has received 1 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Pharvaris has received 75.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Pharvaris and other stocks. Vote “Outperform” if you believe PHVS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PHVS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Pharvaris does not currently pay a dividend.
Dividend Growth
Pharvaris does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pharvaris insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

$28.75

-4.86 (-14.46 %)

(As of 03/5/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive PHVS News and Ratings via Email

Sign-up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter.

Pharvaris (NASDAQ:PHVS) Frequently Asked Questions

Is Pharvaris a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pharvaris in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Pharvaris stock.
View analyst ratings for Pharvaris or view top-rated stocks.

What stocks does MarketBeat like better than Pharvaris?

Wall Street analysts have given Pharvaris a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pharvaris wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for PHVS?

4 analysts have issued 12 month target prices for Pharvaris' shares. Their forecasts range from $41.00 to $51.00. On average, they anticipate Pharvaris' stock price to reach $47.50 in the next year. This suggests a possible upside of 65.2% from the stock's current price.
View analysts' price targets for Pharvaris or view top-rated stocks among Wall Street analysts.

Who are Pharvaris' key executives?

Pharvaris' management team includes the following people:

Mr. Berndt A. E. Modig M.B.A., MBA, CPA, CEO & Exec. Director (Age 62)
Ms. Anna Nijdam M.Sc., R.A., Fin. Director & Principal Accounting Officer (Age 39)
Dr. Jochen Knolle, Chief Scientific Officer & COO (Age 71)
Dr. Peng Lu M.D., Ph.D., Chief Medical Officer (Age 43)
Dr. Anne Lesage Ph.D., Chief Early Devel. Officer (Age 59)
Mr. Morgan Conn Ph.D., Chief Bus. Officer (Age 52)

Who are some of Pharvaris' key competitors?

Some companies that are related to Pharvaris include Abcam plc (ABC.L) (ABC), BTG (BTG), Genus plc (GNS.L) (GNS), MorphoSys (MOR), Seer (SEER), Cullinan Management (CGEM), BioAtla (BCAB), Silverback Therapeutics (SBTX), Nurix Therapeutics (NRIX), Gracell Biotechnologies (GRCL), Kinnate Biopharma (KNTE), Trillium Therapeutics Inc. (TRIL.TO) (TRIL), Concordia International (CXR), PureTech Health (PRTC) and iTeos Therapeutics (ITOS).
View all of PHVS's competitors.

When did Pharvaris IPO?

(PHVS) raised $126 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers.

What is Pharvaris' stock symbol?

Pharvaris trades on the NASDAQ under the ticker symbol "PHVS."

When does Pharvaris' quiet period expire?

Pharvaris' quiet period expires on Wednesday, March 17th. Pharvaris had issued 8,270,500 shares in its initial public offering on February 5th. The total size of the offering was $165,410,000 based on an initial share price of $20.00. During Pharvaris' quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Pharvaris?

Shares of PHVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharvaris' stock price today?

One share of PHVS stock can currently be purchased for approximately $28.75.

How much money does Pharvaris make?

Pharvaris has a market capitalization of $915.40 million.

What is Pharvaris' official website?

The official website for Pharvaris is www.pharvaris.com.

How can I contact Pharvaris?

The company can be reached via phone at 31 71 203 6410.

This page was last updated on 3/6/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here